

SUPPLEMENTAL FIGURE 1. Distribution of propensity scores in patients who received spironolactone ("treated" subjects) and in patients who received eplerenone ("control" subjects), both in the unmatched and in the matched samples.















SUPPLEMENTAL FIGURE 2. Distribution of patients according to the year of

enrollment.



SUPPLEMENTAL TABLE 1. Causes of death in the propensity-score matched sample.

	Spironolactone (N = 76)	Eplerenone (N = 52)
Cardiovascular cause of death	54	30
Heart failure	30	12
Sudden death	21	17
Stroke	1	1
Lower limb ischemia	1	0
Bowel ischemia	1	0
Non-cardiovascular cause of death	21	19
Infection	10	9
Malignancy	7	8
Liver cirrhosis	0	1
Head trauma	1	0
Gastrointestinal bleeding	1	0
Genitourinary bleeding	1	0
Pulmonary veno-occlusive disease	0	1
Chronic obstructive pulmonary disease	1	0
Unknown cause of death (no data)	1	3

SUPPLEMENTAL TABLE 2. Hazard-ratios for the primary and secondary end-points of the study, recalculated by means of a multivariable competing-risk regression model in which the baseline dose of mineralocorticoid receptor antagonists was included as an adjusting covariate.

	HR (95% CI) Eplerenone vs. Spironolactone	P value
Primary end-point		
Death from cardiovascular causes or heart failure hospitalization	0.93 (0.72–1.22)	<mark>0.616</mark>
Secondary end-points		
Death from cardiovascular causes	0.56 (0.35-0.89)	0.014
Heart failure hospitalization	1.05 (0.79–1.40)	0.725
Death from any cause	0.68 (0.48-0.98)	0.039
Death from cardiovascular causes or heart transplantation	0.82 (0.59–1.16)	0.264

SUPPLEMENTAL TABLE 3. Hazard-ratios for the primary and secondary end-points of the study, recalculated by means of a multivariable competing-risk regression model in which the year of study enrollment was included as an adjusting covariate.

	HR (95% CI) Eplerenone vs. Spironolactone	<mark>P value</mark>
<i>Primary end-point</i> Death from cardiovascular causes or heart failure hospitalization	<mark>0.95 (0.72–1.23)</mark>	<mark>0.680</mark>
Secondary end-points		
Death from cardiovascular causes	<mark>0.55 (0.35–0.86)</mark>	<mark>0.008</mark>
Heart failure hospitalization	1.07 (0.81–1.43)	<mark>0.635</mark>
Death from any cause	<mark>0.67 (0.47–0.96)</mark>	0.027
Death from cardiovascular causes or heart transplantation	<mark>0.85 (0.61–1.19)</mark>	<mark>0.354</mark>